TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: [18F]FES PET/CT in PAH

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. Women who are post-menopausal, defined as one of the following~  1. \> 50 years old and a) have not menstruated during the preceding 12 months per medical record review or self-report or b) have follicle-stimulating hormone levels \> 40 IU/L at screening OR~ 2. \< 50 years and follicle-stimulating hormone levels \> 40 IU/L at screening OR~ 3. history of bilateral oophorectomy per medical record review or self-report.~  2. Diagnosis of Pulmonary Arterial Hypertension (PAH) per medical record review.~  3. Patients must be candidates to receive treatment on the companion therapeutic trial Estrogen Receptor-α Inhibitor in Patients with Pulmonary Arterial Hypertension (ERA PAH) (IRB# 824861 ERA PAH)~  4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~* 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician~  2. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.~  3. Ineligible for the therapeutic trial IRB# 824861 ERA PAH entitled Estrogen Receptor Antagonist in Patients with Pulmonary Arterial Hypertension (ERA PAH) (IRB# 824861 ERA PAH)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FES PET/CT scan (Type: None): All subjects will receive an \[18F\]FES PET/CT scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give written informed consent~* Have a glomerular filtration rate (GFR) ≤ 45 mL/min~* Have an expectation of going on hemodialysis or are already on hemodialysis~* Is serum negative for hepatitis B virus (HBV) antibodies, hepatitis C virus (HCV), and human immunodeficiency virus (HIV)~* Have repeated resting blood pressure measurements ≤ 165/105 mmHg~* Women of childbearing potential must be consistently using a highly effective method of birth control~Exclusion Criteria:~* Women who are pregnant, breastfeeding or planning a pregnancy~* Any previous HBV infection~* Previous vaccination (1 or more doses) with any HBV vaccine~* Any previous autoimmune diseases~* Have a diagnosis of chronic renal failure due to autoimmune disease~* Are at high risk for recent exposure to HBV, HCV or HIV~* Received any antibodies within 3 months prior to study entry~* Ever received an injection with DNA plasmids or oligonucleotides~* Received any vaccines within 4 weeks prior to study entry~* Received any other investigational medicinal agent within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1018 ISS-HBsAg-Single (Type: EXPERIMENTAL): Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
- 1018 ISS-HBsAg-Double (Type: EXPERIMENTAL): Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe plaque psoriasis~* Loss of satisfactory response to adalimumab~* Currently receiving or recently discontinued treatment with adalimumab~Exclusion Criteria:~* Active skin conditions that would interfere with evaluations of the effect of investigational product on psoriasis~* Serious medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept 50 mg (Type: EXPERIMENTAL): Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment within 24 hours of hospital admission of patients diagnosed with COVID-19~* Patients with oxygen saturation less than 93 % on room air~* Shortness of breath, with symptom onset within the previous 8 days.~* Female subjects of childbearing potential should take adequate measures to avoid pregnancy~* Signed informed consent by the subject~Exclusion Criteria:~* Patients who are treated with or require high flow nasal cannula, CPAP, intubation, mechanical ventilation, or tracheostomy~* Diagnosis of acute respiratory distress syndrome~* Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart disease, left ventricular dysfunction or myocardial damage, severe pulmonary hypertension and/or unstable hypertension~* Patients receiving drugs that have contraindications with NO.~* Breastfeeding or pregnancy as evidenced by a positive pregnancy test.~* Patients with active pulmonary malignancy or lung transplant~* Patients with a history of frequent epistaxis or significant hemoptysis

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled NO delivered using LungFit™ in addition to SST (Type: EXPERIMENTAL): Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
- Standard of care (Type: NO_INTERVENTION): Control - Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Model Based Fast Anatomical Mapping

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Have AF as follows:~  1. Paroxysmal AF - defined as AF that is non-sustained (terminate without electrical or pharmacologic cardioversion) lasting \< 7 days.~ 2. Persistent AF - defined as AF that is sustained \> 7 days. Episodes of AF which are terminated by electrical or pharmacologic cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified as persistent AF episodes.~* Are planned to undergo a first catheter ablation procedure (prior typical atrial flutter is allowed)~* Have the ability to understand the requirements of the study and sign the informed consent form.~* Are willing to adhere to study restrictions and comply with all post-procedural follow-up requirements~Exclusion Criteria:~* Rheumatic heart disease,~* Current intra-cardiac thrombus~* Class IV HF~* Unable to sign consent~* Unstable angina~* Recent cerebral ischemic events~* Contradiction to anticoagulation~* Prior cardiac surgery~* Complex congenital heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MFAM (Type: EXPERIMENTAL): The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraprostatic MAXimal Simultaneous Boost

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically proven adenocarcinoma of the prostate.~2. Registration must occur within 26 weeks of biopsy.~3. History and physical examination (including digital rectal examination (DRE)) within 8 weeks prior to registration.~4. Patients must have intermediate risk prostate cancer, as defined by:~   * PSA ≤ 20 ng/ml,~  * Gleason ≤ 7,~  * Stage ≤ T2c, and~  * Do not meet criteria for low-risk prostate cancer (Low-risk = All of: PSA ≤ 10 + Gleason ≤ 6 + stage ≤ T2b)~5. Patients must have the following blood tests within two weeks of registration:~   * Prostate specific antigen (PSA), testosterone (TTT), complete blood count (CBC), electrolytes, creatinine.~  * Patients with values for one or more of these tests (not including PSA) that fall outside the normal range will need to be reviewed by the oncologist to determine their eligibility for this study.~6. Patients must have an estimated life expectancy of at least 10 years.~7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.~8. Patients must have no contraindications to high dose pelvic irradiation.~9. Patients must not have received prior radiation therapy to the pelvis.~10. Patients must have no history of inflammatory bowel disease.~11. Patients must not have received prior hormonal therapy or chemotherapy.~12. Patients must not have any hormonal therapy planned as part of the therapeutic intervention.~13. Patients must have no contraindication to MRI scanning.~14. Patients should not have an artificial hip~15. Patients should not have a body mass index (BMI) of \> 32. Note: BMI = weight in kg ÷ (height in metres)2~Exclusion Criteria:~1. Subjects that do not meet inclusion criteria.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMAX (Type: OTHER): There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions.~* A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men undergoing an outpatient prostate biopsy independently indicated by a physician.~* Patients will be selected from the population initially studied with a prostate biopsy for possible prostate cancer~  * sub-group without evidence of cancer~ * sub-group with advanced prostate cancer beyond the currently accepted criteria for surgical treatment,~ * sub-group with indication of radical prostatectomy~* Patients will be recruited from the population of patients from Brigham and Women's Hospital for surgery referred from other institutions/doctors where their biopsy was taken and the diagnosis of prostate cancer was originally made. These patients are not eligible for Aim 1 but will enter the randomized trial (Aim 2 with baseline)~Exclusion Criteria:~* Prostate biopsy patients who do not accept and sign an informed consent form to~  * donate ten ml of blood for fatty acid analysis in red blood cells~ * allow their prostate biopsy to be analyzed as discarded pathological material~ * authorize access to their hospital clinical information for follow up studies~* Patients with a current diagnosis of a condition that might interfere with the measurements of fatty acids in red blood cell membranes such as severe anemia (less than 9g/100m1% hemoglobin~  -- Or~* Diseases of lipid metabolism such as familial dyslipoproteinemia, liver cirrhosis, advanced renal failure, and malabsorption syndrome.~* Exclude from this study patients from (indication of radical prostatectomy) who refuse the surgical recommendation or schedule surgery at a location other than Brigham and Women's Hospital.~* Patients who are not able to complete the full program will not be taken into consideration in the final data analysis.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- omega-3 fatty acids (Type: EXPERIMENTAL): omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
- Corn Oil (Type: PLACEBO_COMPARATOR): Oral 8g once a day for 21 days prior to (biopsy) surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Hospitalisation with signs of preterm birth~* Gestational age at randomisation \>22 weeks (22+0) and \<35 weeks (34+6)~* Good German or English skills~* Written informed consent~Exclusion Criteria:~* Early premature rupture of the membranes (PPROM)~* Factors that make soon delivery likely (pre-eclampsia, suspect cardiotocography, clinical signs of an amniotic infection)~* Body temperature \>38°C~* Cervical opening or cervical length \< 5 mm~* Contraindication for B. pinnatum, lactose or wheat protein allergy~* Taking Bryophyllum 50% chewable tablets or powder 48 h before study inclusion~* Taking psychotropic drugs (Benzodiazepines, antidepressants, neuroleptics)~* Diagnosed psychiatric disease (depression, anxiety disorder, adaptation disorder, post- traumatic stress disorder, bipolar disorder)~* Active participation in another interventional study during the last 4 weeks~* Known or suspected non-compliance with study protocol~* Drug or alcohol abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bryophyllum 50% (Type: ACTIVE_COMPARATOR): Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
- Placebo (Type: PLACEBO_COMPARATOR): Participants of the control group take Placebo chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Topical Capsaicin in the Treatment of Provoked Vestibulodynia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provoked vulvodynia, rated B2a according to 2003 International Society for the Study of Vulvovaginal Disease (ISSVD) classification~* Pain ≥ 4 on Visual Analogic Scale (VAS)~* Subject refractory to at least 2 conventional treatments (tricyclic antidepressants, anticonvulsants at analgesic doses , biofeedback physical therapy, psychological assessment in a context of chronic pain) or to botulinum toxin A~* If a former treatment with botulinum toxin A was performed: patient must be in treatment failure (= no decrease over 50% of the pain 3 months after initiation of the treatment)~* Negative screening test results~* Menopause, surgically sterilized women or women using effective contraceptive method~* Good understanding and predictable adherence to the protocol~* Beneficiary/affiliated to French social security/social healthcare~* Signed Informed Consent Form~Exclusion Criteria:~* Predictable poor adherence~* Pregnant or breastfeeding women~* Diabetes mellitus type 1 or type 2~* Major mental disorders~* Underlying etiology such as chronic vulvar disease~* Initial vulvar erythema~* Vulnerable subjects (particularly adults under guardianship)~* Ongoing medical treatment with tricyclic antidepressants or anticonvulsants at analgesic doses~Subject refractory to conventional treatments (tricyclic antidepressants and benzodiazepines doses analgesics, physiotherapy type of biofeedback)~Good understanding and predictable adherence to the protocol beneficiary/affiliated to French social security/social healthcare signed Informed Consent Form

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Capsaicin patch (Type: EXPERIMENTAL): Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent and authorization of use and disclosure of protected health information~* Age at least 18 years~* For the study group, patients diagnosed with Stargardt disease, age related macular degeneration and diabetic retinopathy by the investigators, based on clinical phenotype~* For the control group, patients with no retinal disease undergoing cataract surgery will be eligible.~Exclusion Criteria:~• None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Stargardt disease, AMD, DR patients (Type: None): Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
- Controls (Type: None): Patients without retinal disease who will be undergoing cataract surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-75 years old with newly diagnosed histologically proven resected melanoma~2. Stage: IIa (T2b, T3a), IIb (T3b T4a) and IIc (T4b), N0, M0~3. Signed informed Consent~4. Willingness to provide blood samples~5. Performance Status of 0-1~6. Hematopoietic functionality at the entry of the study: leukocytes, platelets, haemoglobin and neutrophiles within the normal limits of laboratory references~7. Hepatic and renal functionality at the entry of the study within the normal range of each laboratory~8. Serum and urinary calcium within the upper limit of laboratory references.~Exclusion Criteria:~1. Primary not cutaneous melanoma~2. Clinical/radiological evidence or laboratory/pathology report of not completely resected melanoma~3. History of cancer (other than Carcinoma in situ (CIN) and non melanoma skin cancere (NMSC)~4. Current daily use of at least 600 IU/day of supplemental vitamin D or calcitriol or high dose of calcium therapy (e.g. calcium citrate with vitamin D) within the prior 6 months greater than 600 mg calcium per day during study~5. History of recurrent renal calculi or hypercalcemia (\>10mg/dl), current and chronic use of oral corticosteroids~6. History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, Crohn disease or tropical sprue)~7. History of small intestinal resection (e.g., ileal bypass surgery for treatment of morbid obesity resection \> 50 % of slim bowel)~8. Hypersensitivity to cholecalciferol or one of its components~9. Chronic liver disease, chronic renal disease, or renal dialysis~10. History of parathyroid disease and sarcoidosis~11. Pregnancy or breast feeding or planning on becoming pregnant during the 3 years of treatment~12. Chronic alcoholism~13. Any medical condition that in the physician's opinion would potentially interfere with vitamin D absorption, such as celiac sprue, ulcerative colitis, patients treated pharmacologically for obesity~14. Any logistic condition that do not allow follow-up of the disease of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Vitamin D3 administration
- placebo (Type: PLACEBO_COMPARATOR): matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues